ISN ACT Webinar: Hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
This webinar focuses on HIF-PHIs for the treatment of anemia in chronic kidney disease (CKD), a key component of advanced CKD care.
The advent of erythropoiesis-stimulating agents (ESAs) led to dramatic reductions in blood transfusions and associated morbidity. However, after meta-analysis of trials showed ESA-based normalization of hemoglobin levels led to inferior outcomes than approaches targeting lower hemoglobin levels, it was clear that there were still unmet needs in the management of anemia and its associated clinical outcomes in the context of CKD.
In recent years, several large clinical trials of HIF-PHIs have been completed testing a range of agents in different patient populations, informing the role of these agents in clinical practice.
- To understand the issues underpinning the management of anaemia in different CKD populations.
- To understand and interpret the findings of the large Phase 2 trials of the HIF-PHI trials
- Sanghani, N. S., & Haase, V. H. (2019). Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Advances in chronic kidney disease, 26(4), 253–266.
- Kidney International (2021) 99, 1280–1295;
- Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology : JASN, 23(10), 1631–1634.
- Haase V. H. (2021). Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney international supplements, 11(1), 8–25.
This webinar is supported by Astellas